Drug Profile
Endothelial stem cell therapy - Regen BioPharma
Alternative Names: Aplastic anemia stem cell therapy - Regen BioPharma; Autologous stromal vascular fraction cells - Regen BioPharma; HemaXellerate I™; HemaXellerate™Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Regen BioPharma
- Developer Cascade LifeSciences; Pan American Cancer Treatment Center; Regen BioPharma
- Class Stem cell therapies
- Mechanism of Action Bone marrow cell stimulants; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Aplastic anaemia
- No development reported Myelosuppression
Most Recent Events
- 04 Apr 2024 HemaXellerate is still in preclinical development for Aplastic-anaemia in USA (Parenteral) (Regen Biopharma pipeline, April 2024)
- 02 Apr 2024 Regen BioPharma plans a phase I trial for Aplastic anaemia (Regen Biopharma pipeline, April 2024)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Myelosuppression in Mexico (Parenteral)